Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Friday 20 November →